Advertisement

Topics

Myriad: FDA To Review BRACAnalysis CDx Supplementary PMA

07:43 EDT 18 Jun 2018 | FinanzNachrichten

WASHINGTON (dpa-AFX) - Myriad Genetics, Inc. (MYGN) announced that the U.S. FDA has accepted its supplementary premarket approval (sPMA) application for BRACAnalysis CDx to be used as a companion ...

Original Article: Myriad: FDA To Review BRACAnalysis CDx Supplementary PMA

NEXT ARTICLE

More From BioPortfolio on "Myriad: FDA To Review BRACAnalysis CDx Supplementary PMA"

Advertisement
Quick Search
Advertisement
Advertisement